Zhejiang Orient Gene Biotech Co., Ltd (SHA:688298)
China · Delayed Price · Currency is CNY 25.40
+0.22 (0.87%)
At close: Jan 23, 2026
SHA:688298 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
Net Income | -479.5 | -529.02 | -397.58 | 2,068 | 4,920 | 1,677 | Upgrade |
Depreciation & Amortization | 204.24 | 204.24 | 165.49 | 86.56 | 37.31 | 7.44 | Upgrade |
Other Amortization | 24.12 | 24.12 | 18 | 8.51 | 2.27 | 1.67 | Upgrade |
Loss (Gain) From Sale of Assets | -0.99 | -0.99 | 0.18 | 0.01 | -0.01 | - | Upgrade |
Asset Writedown & Restructuring Costs | 81.75 | 81.75 | 63.86 | 366.58 | 0.05 | 75.49 | Upgrade |
Loss (Gain) From Sale of Investments | -24.6 | -24.6 | -48.85 | -7.66 | -11.22 | -15.01 | Upgrade |
Provision & Write-off of Bad Debts | 30.1 | 30.1 | 30.17 | -6.44 | 32.55 | 29.37 | Upgrade |
Other Operating Activities | 154.75 | -8.24 | 96.57 | 378.84 | 109.18 | 26.45 | Upgrade |
Change in Accounts Receivable | -109.37 | -109.37 | 210.28 | 825.4 | -692.05 | -640.46 | Upgrade |
Change in Inventory | 1.91 | 1.91 | -86.23 | -775.13 | -98.7 | -379.08 | Upgrade |
Change in Accounts Payable | -11.52 | -11.52 | -1,670 | 172.34 | 928.52 | 1,048 | Upgrade |
Change in Other Net Operating Assets | 15.78 | 15.78 | - | - | - | - | Upgrade |
Operating Cash Flow | -135.81 | -348.33 | -1,646 | 2,996 | 5,204 | 1,790 | Upgrade |
Operating Cash Flow Growth | - | - | - | -42.43% | 190.67% | 3202.41% | Upgrade |
Capital Expenditures | -692.23 | -924.09 | -996.05 | -1,052 | -507.87 | -126.93 | Upgrade |
Sale of Property, Plant & Equipment | 7.75 | 7.51 | 0.81 | 2.58 | 1.79 | 0.09 | Upgrade |
Cash Acquisitions | 1.65 | -320.76 | -78.52 | -184.87 | -43.71 | - | Upgrade |
Investment in Securities | 596.87 | 678.26 | 81.54 | -1,076 | 228.15 | -437 | Upgrade |
Other Investing Activities | -644.32 | -111.06 | -1,126 | -65.22 | - | 15.01 | Upgrade |
Investing Cash Flow | -730.27 | -670.15 | -2,118 | -2,376 | -321.64 | -548.84 | Upgrade |
Long-Term Debt Issued | - | 300.75 | 772 | 50 | - | - | Upgrade |
Total Debt Issued | 356.05 | 300.75 | 772 | 50 | - | - | Upgrade |
Long-Term Debt Repaid | - | -459.27 | -331.82 | -6.21 | -6.97 | -26.96 | Upgrade |
Total Debt Repaid | -607.67 | -459.27 | -331.82 | -6.21 | -6.97 | -26.96 | Upgrade |
Net Debt Issued (Repaid) | -251.62 | -158.52 | 440.18 | 43.79 | -6.97 | -26.96 | Upgrade |
Issuance of Common Stock | - | - | - | - | - | 578.9 | Upgrade |
Repurchase of Common Stock | -276.95 | -276.95 | - | - | - | - | Upgrade |
Common Dividends Paid | -11.29 | -16.63 | -351.14 | -742.04 | -504.67 | -25.29 | Upgrade |
Other Financing Activities | 242.39 | 0.36 | -39.51 | - | 2.47 | -23.36 | Upgrade |
Financing Cash Flow | -297.46 | -451.74 | 49.54 | -698.25 | -509.17 | 503.29 | Upgrade |
Foreign Exchange Rate Adjustments | 39.09 | 51.89 | 85.85 | 536.65 | -75.44 | -29.78 | Upgrade |
Net Cash Flow | -1,124 | -1,418 | -3,628 | 458.62 | 4,298 | 1,715 | Upgrade |
Free Cash Flow | -828.04 | -1,272 | -2,642 | 1,944 | 4,696 | 1,663 | Upgrade |
Free Cash Flow Growth | - | - | - | -58.60% | 182.32% | 3831.28% | Upgrade |
Free Cash Flow Margin | -98.33% | -153.69% | -322.09% | 22.17% | 46.18% | 50.94% | Upgrade |
Free Cash Flow Per Share | -4.30 | -6.47 | -13.09 | 9.64 | 23.29 | 8.43 | Upgrade |
Cash Income Tax Paid | - | -13.59 | -24.31 | 1,112 | 260.08 | 9.23 | Upgrade |
Levered Free Cash Flow | -692.58 | -1,255 | -2,379 | 1,513 | 3,361 | 1,274 | Upgrade |
Unlevered Free Cash Flow | -684.82 | -1,243 | -2,368 | 1,517 | 3,362 | 1,274 | Upgrade |
Change in Working Capital | -125.68 | -125.68 | -1,573 | 101.82 | 113.54 | -12.46 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.